Sarah Gheuens - Mar 1, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Medical Officer
Signature
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol
AGIO
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:11 PM
Previous filing
Feb 23, 2022
Next filing
Dec 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Award $0 +11.5K $0.00 11.5K Mar 1, 2022 Common stock 11.5K Direct F1, F2
transaction AGIO Stock options (right to buy) Award $0 +41K $0.00 41K Mar 1, 2022 Common stock 41K $32.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2 The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
F3 This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.